摘要
Objective To evaluate the performance of Mycobacterium tuberculosis and rifampicin resistance mutation detection kit(InnowaveDX MTB/RIF,referred to as"InnowaveDX")in diagnosing tuberculosis and rifampicin resistance using sputum samples.Methods From June 19,2020 to May 16,2022,patients with suspected tuberculosis were prospectively and consecutively enrolled in Hunan Provincial Tuberculosis Prevention and Control Institute,Henan Provincial Hospital of Infectious Diseases and Wuhan Jinyintan Hospital.A total of 1328 patients with suspected tuberculosis were finally included.
作者
王艳萍
WANG Yanping(Dept Emerg,Hubei Prov TCM Hosp,Wuhan 430060)